Economic impact of compliance to treatment with antidiabetes medication in type 2 diabetes mellitus: a review paper

References

• Lerman I. Adherence to treatment: the key for avoiding long-term complications of diabetes. Arch Med Res 2005;36:300-306
   PubMed Web of Science ®Google Scholar
• Revicki D, Frank L. Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies. Pharmacoeconomics 1999;15:423-434
   PubMed Web of Science ®Google Scholar
• Cramer J, Roy A, Burrell A, Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-47
   PubMed Web of Science ®Google Scholar
• Hughes D, Cowell W, Koncz T, Cramer J. Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. Value Health 2007;10:498-509
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care 2003;26:917-932
   PubMed Web of Science ®Google Scholar
• Menzin J, Langley-Hawthorne C, Friedman M, Potential short-term economic benefits of improved glycemic control: a managed care perspective. Diabetes Care 2001;24:51-55
   PubMed Web of Science ®Google Scholar
• Wagner EH, Sandhu N, Newton KM, Effect of improved glycemic control on health care costs and utilization. JAMA 2001;285:182-189
   PubMed Web of Science ®Google Scholar
• Salas M, Hughes D, Zuluaga A, Costs of medication non-adherence in patients with diabetes mellitus: a systematic review and critical analysis of the literature. Value Health 2009;12:915-922
   PubMed Web of Science ®Google Scholar
• Lee W, Balu S, Cobden D, Prevalence and economic consequences of medication adherence in diabetes: a systematic literature review. Manag Care Interface 2006;19:31-41
   PubMedGoogle Scholar
• American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005;28:S4-36
   PubMed Web of Science ®Google Scholar
• Shenolikar RA, Balkrishnan R. Oral antidiabetes medication adherence and health care utilisation among Medicaid-enrolled type 2 diabetic patients beginning monotherapy. Diabetes Care 2008;31(2):e5
   Google Scholar
• Pawaskar M, Camacho F, Anderson R, Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. Clin Ther 2007;29:1294-1305
   Web of Science ®Google Scholar
• Shenolikar R, Balkrishnan R, Camacho F, Comparison of medication adherence and associated health care costs after introduction of pioglitazone treatment in African Americans versus all other races in patients with type 2 diabetes mellitus: a retrospective data analysis. Clin Ther 2006;28:1199-1207
   PubMed Web of Science ®Google Scholar
• Cobden D, Lee WC, Balu S, Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Pharmacotherapy 2007;27:948-962
   PubMed Web of Science ®Google Scholar
• Karve S, Cleves M, Helm M, An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. Med Care 2008;46:1125-1133
   PubMed Web of Science ®Google Scholar
• Balkrishnan R, Rajagopalan R, Shenolikar RA, Outcomes associated with introduction of thiazolidinedione therapy in Medicaid enrolled patients with type 2 diabetes: an updated and expanded retrospective analysis. Curr Med Res Opin 2006;22:551-559
   PubMed Web of Science ®Google Scholar
• Sokol M, McGuigan K, Verbrugge R, Epstein R. Impact of medication adherence on hospitalisation risk and healthcare cost. Med Care 2005;43:521-530
   PubMed Web of Science ®Google Scholar
• Hepke K, Martus M, Share D. Costs and utilisation associated with pharmaceutical adherence in a diabetic population. Am J Manag Care 2004;10:144-151
   PubMed Web of Science ®Google Scholar
• Balkrishnan R, Rajagopalan R, Camacho F, Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther 2003;25:2958-2971
   PubMed Web of Science ®Google Scholar
• Cherry J, Moffatt T, Rodriguez C, Dryden K. Diabetes disease management program for an indigent population empowered by telemedicine technology. Diabetes Technol Ther 2002;4:783-791
   PubMedGoogle Scholar
• Ciechanowski P, Katon W, Russo J. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch Intern Med 2000;160:3278-3285
   PubMed Web of Science ®Google Scholar
• Lee W, Balu S, Cobden D, Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther 2006;28:1712-1725
   PubMed Web of Science ®Google Scholar
• Steiner J, Koepsell T, Fihn S, Inui T. A general method of compliance assessment using centralized pharmacy records. Med Care 1988;26:814-823
   PubMed Web of Science ®Google Scholar
• Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992;45:197-203
   PubMed Web of Science ®Google Scholar
• Clark D, von Korff M, Saunders K, A chronic disease score with empirically derived weights. Med Care 1995;33:783-795
   PubMed Web of Science ®Google Scholar
• D'Hoore W, Sicotte C, Tilquin C. Risk adjustment in outcome assessment: the Charlson comorbidity index. Methods Inf Med 1993;32:382-387
   PubMed Web of Science ®Google Scholar
• Ellis RP, Ash A. Refinements to the Diagnostic Cost Group (DCG) model. Inquiry 1995–1996;32(4):418-429
   PubMedGoogle Scholar
• Stephens JM, Botteman MF, Hay JW. Economic impact of antidiabetic medications and glycaemic control on managed care organizations: a review of the literature. Manag Care Pharm 2006;12:130-142
   PubMed Web of Science ®Google Scholar
• Leiter LA, Yale JF, Chiasson JL, Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemic management. Can J Diabetes 2005;29:186-192
   Google Scholar
• Amiel S, Dixon T, Mann R, Jameson K. Hypoglycaemia in type 2 diabetes. Diabet Med 2008;25:245-254
   PubMed Web of Science ®Google Scholar
• Falagas ME, Pitsouni EI, Malietzis GA. Pappas G. Comparison of PubMed, Scopus, Web of Science, and Google Scholar: strengths and weaknesses. FASEB J 2008;22:338-342
   PubMed Web of Science ®Google Scholar